Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 166

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 166
---
4 and 2023, no vendor contributed more than 10% of total direct cost of
the Group. NewGenIvf’s procurement team is experienced in selecting cost-effective supplies as well as selecting reliable suppliers.
NewGenIvf’s major suppliers are pharmaceutical companies.

Competition

NewGenIvf believes that it
is a long-standing provider of ARS in Asia Pacific that competes primarily based on the following competitive factors:

| ● | the value and comprehensiveness of the solutions; |

| ● | treatment that is effective and achieves desired outcomes; |

| ● | clients’ experience, including dedicated patient education, clinical guidance and emotional support; and |

| ● | access to a network of high-quality fertility specialists. |

NewGenIvf competes primarily
with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably robust and
integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf’s competitors may compete in a variety
of ways, including by providing better services, having established local connections, fulfilling evolving client needs, as well as conducting
brand promotions and other marketing activities.

As NewGenIvf may introduce
new ancillary services and other companies may introduce similar fertility services as NewGenIvf’s, NewGenIvf may become subject
to additional competition.

Facilities

As of December 31, 2024, in
addition to its clinics, NewGenIvf leased one property in Hong Kong with an aggregate square footage of approximately 8,000 for its
administration support offices. NewGenIvf also operates its medical facilities as described above in “— Network of Facilities”
above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs.

<div align='center'>97

PRINCIPAL SHAREHOLDERS</div>

The following table sets forth
information with respect to beneficial ownership of our Class A ordinary shares and Class B ordinary shares as of the date of this prospectus
by:

| ● | Each                                                                                                                                  
 person who is known by us to beneficially own more than 5% of our issued and outstanding Class A ordinary shares and Class B ordinary 
 shares;                                                                                                                               |

| ● | Each                                                                 
 of our director, director nominees and named executive officers; and |

| ● | All                                                
 directors and named executive officers as a group. |

|                                                |     | Ordinary shares beneficially owned prior to this offering |